Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2017 Q2- Text added to 2017 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
8th grade Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
8th grade Avg
|
New words:
administered, agonist, aid, antagonist, Bavarian, burden, cardioversion, colon, disruption, domestic, eligible, EMANATE, ENHANZE, eventually, exploring, fluoropyrimidine, futile, Halozyme, Humana, humanitarian, IFM, immune, innate, intermediate, intravenously, irinotecan, large, lymph, mCRC, mm, modulate, negotiation, nominated, Nordic, NVAF, occurrence, ovarian, oxaliplatin, pathologic, population, prescribing, prostate, Prostvac, repaid, resident, restoration, restore, restoring, Rubraca, rucaparib, SCLC, step, STING, stomach, subcutaneously, successful, Supreme, technology, testing, Teva, topline, undergoing, USA
Removed:
brentuximab, cHL, Designation, extend, updated, vedotin
Valuein 2017 Q2 filing- Value in 2017 Q3 filing
Original filings
Filing view